Safety and Efficacy Study of RA101495 in Subjects With Generalized Myasthenia Gravis

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2017
The purpose of the study is to evaluate the safety and efficacy of RA101495 in patients with generalized Myasthenia Gravis (gMG). Subjects will be randomized in a 1:1:1 ratio to receive daily SC doses of 0.1 mg/kg RA101495, 0.3 mg/kg RA101495, or matching placebo for 12 weeks.
Epistemonikos ID: 1dd9197e521334e41f0f8e57850cf642c2917d9e
First added on: May 21, 2024